Stockscreener 앱 받기
7.81
2.76%
0.21
시간 외 거래:
7.81
전일 마감가:
$7.60
열려 있는:
$7.595
하루 거래량:
3.38M
Relative Volume:
0.69
시가총액:
$2.80B
수익:
$9.68M
순이익/손실:
$-250.64M
주가수익비율:
-5.5794
EPS:
-1.3998
순현금흐름:
$-89.83M
1주 성능:
-8.55%
1개월 성능:
+14.85%
6개월 성능:
+82.90%
1년 성능:
+144.83%
1일 변동 폭
$7.475
$7.8399
1주일 범위
$7.35
$8.60
52주 변동 폭
$2.99
$8.98
Precigen Inc Stock (PGEN) Company Profile
명칭
Precigen Inc
전화
301-556-9900
주소
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
7.81 | 2.77B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-15 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-03-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-05-23 | 개시 | JP Morgan | Neutral |
| 2022-11-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-25 | 개시 | Stifel | Buy |
| 2021-02-22 | 개시 | Wells Fargo | Overweight |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-05-08 | 개시 | H.C. Wainwright | Buy |
모두보기
Precigen Inc 주식(PGEN)의 최신 뉴스
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? - Yahoo Finance
uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research
Precigen: FDA’s Platform Technology Designation And Institutional Crossover Effect (PGEN) - Seeking Alpha
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Yahoo Finance
Total assets of Precigen Inc – HAN:I5X - TradingView
Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs? - Insider Monkey
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today? - Stocktwits
Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap? - Yahoo Finance
Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies - Yahoo Finance
B. Riley Securities initiates coverage of Precigen with Buy rating, $12 price target - TradingView
Precigen stock hits 52-week high at 8.05 USD - Investing.com
B.Riley initiates Precigen stock coverage with buy on drug launch - Investing.com Australia
$Precigen (PGEN.US)$ ready for the next leg higher - Moomoo
PGEN Initiates Coverage On B. Riley Securities -- Rating Set to Buy - GuruFocus
B.Riley initiates Precigen stock coverage with buy on drug launch By Investing.com - Investing.com South Africa
Precigen Initiated at Buy by B. Riley Securities - Moomoo
Form 4 Precigen Inc For: 25 September By Investing.com - Investing.com Canada
Form 4 Precigen Inc For: 25 September - Investing.com India
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos? - Yahoo Finance
Precigen's AdenoVerse Receives FDA Platform Technology Designation - marketscreener.com
PGEN Looks 47.9% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
FDA grants platform technology status to Precigen’s AdenoVerse By Investing.com - Investing.com Canada
FDA grants platform technology status to Precigen’s AdenoVerse - Investing.com
September 2026's Leading Growth Companies With Insider Backing - simplywall.st
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform - TradingView
Precigen (PGEN) Stock May Be Fully Valued On Its Current Sales Base - Yahoo Finance
Precigen, Inc. (PGEN) Stock Analysis: A 84% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Precigen stock hits 52-week high at 7.74 USD By Investing.com - Investing.com Nigeria
Precigen stock hits 52-week high at 7.74 USD - Investing.com
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock? - finance.yahoo.com
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026? - Yahoo Finance
Precigen Insider Sold Shares Worth $1,376,400, According to a Recent SEC Filing - Yahoo Finance
Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock - simplywall.st
Precigen (PGEN) Director Jeffrey Kindler Sells 185,000 Shares - GuruFocus
Precigen director Jeffrey Kindler sells $1.38m in stock By Investing.com - Investing.com Australia
Precigen (PGEN) director sells 185K shares in one day - Stock Titan
Does Reliance On Papzimeos Skew Precigen’s (PGEN) Risk Profile Or Validate Its Focused Strategy? - Yahoo Finance
Is Precigen (PGEN) Undervalued After Reaching Quarterly Profitability? - sahmcapital.com
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Precigen (PGEN) director plans 185,000-share 2026 sale - Stock Titan
Precigen COO Rutul Shah sells $375,000 in shares By Investing.com - Investing.com South Africa
Precigen CCO Phil Tennant sells $593,745 in stock By Investing.com - Investing.com Nigeria
Precigen Insider Sold Shares Worth $375,000, According to a Recent SEC Filing - marketscreener.com
Precigen (PGEN) insider lines up another stock sale after four recent trades - Stock Titan
Precigen (NASDAQ: PGEN) officer to sell 79,166 shares in 2026 - Stock Titan
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - Investing News Network
3 Growth Companies With High Insider Ownership And 55% Earnings Growth - Sahm
Precigen Inc (PGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Precigen Inc 주식 (PGEN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KINDLER JEFFREY B | Director |
Aug 26 '26 |
Sale |
7.44 |
185,000 |
1,376,400 |
17,100 |
5.32%
자본화:
|
볼륨(24시간):